Check-Cap Ltd. Announces $10M Registered Direct Offering
Check-Cap Ltd. Announces $10M Registered Direct Offering
ISFIYA, Israel, March 1, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test, to detect polyps before they may transform into colorectal cancer (CRC), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 20,000,000 of the Company's ordinary shares and accompanying warrants to purchase up to an aggregate of 15,000,000 of the Company's ordinary shares in a registered direct offering. Each ordinary share is being sold together with one warrant to purchase 0.75 ordinary share at a combined offering price of $0.50 per ordinary share and accompanying warrant. The warrants will have a term of five years following the date of issuance, be exercisable immediately and have an exercise price of $0.65 per ordinary share. The registered direct offering is expected to close on or about March 3, 2022, subject to satisfaction of customary closing conditions.
以色列ISFIYA 2022年3月1日電Check-Cap Ltd.(“公司”或“Check-Cap”)(納斯達克代碼：CHEK)，(納斯達克代碼：CHEKZ)是一家臨牀階段醫療診斷公司，正在推進C-SCAN®的開發，這是第一種也是唯一一種對患者友好的、免準備的篩查測試，可以在息肉可能轉化為結直腸癌之前發現它們。本公司今天宣佈，已與數家機構及認可投資者就買賣本公司20,000,000股普通股及附隨認股權證訂立最終協議，以登記直接發售最多15,000,000股本公司普通股。每股普通股將與一份認股權證一起出售，以購買0.75股普通股，合併發行價為每股普通股0.50美元和隨附的認股權證。認股權證的有效期為發行之日起5年，可立即行使，行使價為每股普通股0.65美元。登記的直接發行預計將在2022年3月3日左右結束，前提是滿足慣常的結束條件。